RPA2 and breast carcinoma: In the whole cohort, low RPA2 was associated with poor breast cancer-specific survival (BCSS) (P < 0.0001) (Fig. 2D) and distant metastasis-free survival (DMFS) (P = 0.001) (Supplementary Fig. 3A).